Menu
Search
Menu
Search
PARTNER PRESS RELEASE | NEW YORK
09.02.2022
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced it has signed an agreement with NUVISAN, a European CRO/CDMO with topical manufacturing capabilities in Sophia-Antipolis, France, to manufacture clinical batches of HT-001 topical drug product for its upcoming CLEER-001 clinical trial for cancer patients. HT-001 is a novel topical therapy in development for treatment of cutaneous toxicities associated with Epidermal Growth Factor Receptor (EGFR) inhibitor cancer therapy.
PRESS RELEASE | BERLIN & BRISBANE
28.07.2021
The NUVISAN group, a Contract Research Organization (CRO) and Contract Manufacturing Organization (CDMO), and ALS Limited, a global company in the testing, inspection and certification business, today announced the signing of a long term strategic partnership to open new markets. ALS Limited invests into a 49% stake of the NUVISAN group to expand its life sciences portfolio. The global testing specialist with its headquarters in Brisbane/ Australia supports NUVISAN's expansion strategy with its worldwide network.
read complete press release | english version | PDF | 147 KB
Komplette Pressemitteilung lesen | deutsche Version | PDF | 148 KB
COMPANY INFORMATION | NEU-ULM | BERLIN
01.07.2021
NUVISAN and Innovation Campus Berlin now virtually gathered
under one roof
We are delighted to officially announce the launch of our brand new website, www.nuvisan.com, providing our visitors with an easier way to learn about all NUVISAN’s solutions from the early drug discovery with target identification to the proof of concept in patient.
PRESS RELEASE | BERLIN
19.04.2021
ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and NUVISAN Innovation Campus Berlin (ICB) GmbH, a fully integrated contract research service provider for drug discovery and early development programs, today announced a non-exclusive license agreement granting NUVISAN ICB access to ERS Genomics’ CRISPR/Cas9 patent portfolio.
COMPANY INFORMATION | BERLIN | NEU-ULM
17.11.2020
Since the late 2019 onset of Coronavirus in Asia, NUVISAN’s management has been following the development of the disease, assessing its potential impact and anticipated precautionary measures to make sure employees are safe and to secure business continuity.
PRESS RELEASE | BERLIN | NEU-ULM
18.08.2020 English Version
INNOVATION CAMPUS BERLIN is a proud Partner of Europe’s Largest Initiative to Accelerate Therapy Development for COVID-19 and Future Coronavirus Threats which is launched today in cooperation with the European Union, the European Federation of Pharmaceutical Industries, Associations (EFPIA) companies and IMI-Associated Partners.
PRESS RELEASE | BERLIN | NEU-ULM
01.07.2020
On the 1st of July, the "INNOVATION CAMPUS BERLIN" (ICB), a subsidiary of NUVISAN GmbH/ Neu-Ulm officially opened. NUVISAN has taken over a large part of the Berlin-based pharmaceutical research unit, focused on the field of small molecule active ingredients, from Bayer AG and agreed on a strategic partnership.
PRESS RELEASE | BERLIN & NEU-ULM
11.02.2020
Das Pharma-Service Unternehmen NUVISAN hat mit Bayer die Übernahme eines großen Teils der in Berlin ansässigen Pharmaforschung auf dem Gebiet kleinmolekularer Wirkstoffe vereinbart und komplettiert damit sein Leistungsspektrum auf dem Gebiet der präklinischen Forschung.
